20 ADJUVANT HORMONE THERAPY NORMALIZES LIFE EXPECTANCY IN MANY PATIENTS WITH NON-METASTASIZED PROSTATE CANCER. AN EPIDEMIOLOGIC ASSESSMENTMedWire News: The presence of even small tumor-cell deposits in the lymph nodes of patients with early oral and oropharyngeal squamous cell carcinoma (SCC) reflects...
From a molecular genetic viewpoint, the intervention eliminates only the easiest adversary but cannot prevent cancer-related death. Therefore, benefits and risks must be carefully and critically considered. Cytoreductive nephrectomy is not beneficial if treatment-induced morbidity will substantially affect ...
Adjuvant RT did not improve prostate cancer-specific mortality at 5 years (RD -0.01; 95% CI -0.03 to 0.00). Adjuvant RT did not reduce metastatic disease at 5 years (RD -0.00; 95% CI -0.04 to 0.03), but reduced it at 10 years (RD -0.11; 95% CI -0.20 to -0.01). It improved...